Advertisement
Australian researchers say they have identified a way to tell straight away whether someone presenting to a hospital with COVID-19 will develop severe symptoms of the disease.
The finding has the potential to help doctors get ahead of the virus in patients who are at serious risk from the disease, giving them treatments to head off the worst of the symptoms.
The researchers say the biomarker is present from day 0 and is a direct indicator of whether a patient will end up in the ICU with severe symptoms.
Credit:Penny Stephens
The research team from QUT’s Centre for Genomics and Personalised Health and School of Biomedical Sciences had been working on identifying biomarkers for lung cancer.
Leigh F. Capule, Migrations Manager I GSC Philippines, HSBC. Photo: HSBC
Leigh is a pioneer member of the HSBC (HSBA.L) Pride + Ally Network in GSC Philippines. Under Leigh’s leadership a number of significant initiatives and company policy changes were made, including the establishment of both gender neutral and gender preference restrooms, the inclusion of same sex and domestic partners in their insurance coverage and inclusion of treatment of HIV/AIDS in HMO coverage.
Leigh took the lead in the D&I forum held in India in sharing Philippines Pride best practices and initiatives and established an annual PAN GSC SOGIE Awareness session, which she personally facilitates. In addition, she played a critical role in the establishment of Pride ERGs in GSC India and China.
Global Auto-Immune Diseases Diagnostic Testing Device Pipeline Assessment 2020 - ResearchAndMarkets com tullahomanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tullahomanews.com Daily Mail and Mail on Sunday newspapers.
In Depth: Questions Persist Over China’s Vaccine Export Deals
Freezer supplier Froilabo is the only company in France capable of storing Covid-19 vaccines, which require strict temperature conditions.
China’s experimental coronavirus vaccines are on the move. Global procurement data shows that three Chinese firms have inked deals to supply hundreds of millions of vials to the world in bilateral agreements with nations like Indonesia and Brazil.
The flashier mRNA vaccines of Pfizer-BioNTech and Moderna are more adaptable and have produced enviable results, but keeping them cold enough to prevent their delicate strands of genetic material from falling apart in transit is a major challenge.